Interestingly, a recent study showed that intermittent fasting regimens (fasting for 24 h two days a week) prevent and improve NASH and fibrosis, and limit the development of HCC; Specifically, PPARα and PCK1 are liver performers that produce beneficial effects in NASH during fasting; Overexpression of PCK1 reduces lipid accumulation and liver steatosis, preventing NASH transformation into liver cancer [27]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.